SV2017005478A - Sal de tosilato n-[3-[(4ar,7as)-2-amino-6-(5-fluoropirimidina-2-il)-4,4a,5,7-tetrahidropirrolo[3,4-d][1,3]tiazina-7a-il]-4-fluoro-fenil]-5-metoxi-pirazina-2-carboxamida - Google Patents
Sal de tosilato n-[3-[(4ar,7as)-2-amino-6-(5-fluoropirimidina-2-il)-4,4a,5,7-tetrahidropirrolo[3,4-d][1,3]tiazina-7a-il]-4-fluoro-fenil]-5-metoxi-pirazina-2-carboxamidaInfo
- Publication number
- SV2017005478A SV2017005478A SV2017005478A SV2017005478A SV2017005478A SV 2017005478 A SV2017005478 A SV 2017005478A SV 2017005478 A SV2017005478 A SV 2017005478A SV 2017005478 A SV2017005478 A SV 2017005478A SV 2017005478 A SV2017005478 A SV 2017005478A
- Authority
- SV
- El Salvador
- Prior art keywords
- tetrahydropirrolo
- pirazina
- carboxamida
- metoxi
- fluoro
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
LA PRESENTE INVENCIÓN SE REFIERE A UNA 10 SAL DE TOSILATO DE N-[3-[(4AR,7AS)-2-AMINO-6-(5-FLUOROPIRIMIDIN-2-IL)-4,4A,5,7-TETRAHIDROPIRROLO[3,4-D][1,3]TIAZIN-7A-IL]-4-FLUORO-FENIL]-5-METOXI-PIRAZINA-2-CARBOXAMIDA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562109733P | 2015-01-30 | 2015-01-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SV2017005478A true SV2017005478A (es) | 2018-02-09 |
Family
ID=55275232
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SV2017005478A SV2017005478A (es) | 2015-01-30 | 2017-07-06 | Sal de tosilato n-[3-[(4ar,7as)-2-amino-6-(5-fluoropirimidina-2-il)-4,4a,5,7-tetrahidropirrolo[3,4-d][1,3]tiazina-7a-il]-4-fluoro-fenil]-5-metoxi-pirazina-2-carboxamida |
Country Status (41)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR103406A1 (es) * | 2015-01-30 | 2017-05-10 | Lilly Co Eli | Sal de tosilato |
| WO2019094608A1 (en) | 2017-11-08 | 2019-05-16 | Denali Therapeutics Inc. | Anti-bace1 antibodies and methods of use thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT401651B (de) * | 1994-06-14 | 1996-11-25 | Biochemie Gmbh | 7-(2-(2-aminothiazol-4-yl)-2-(z)- hydroximinoacetamido)-3-n,n- dimethylcarbamoyloxymethyl-3-cephem-4- |
| CN101939306A (zh) * | 2007-12-07 | 2011-01-05 | 美国辉瑞有限公司 | 反式-n-异丁基-3-氟-3-[3-氟-4-(吡咯烷-1-基-甲基)-苯基]环丁烷甲酰胺的甲苯磺酸盐 |
| SI2233474T1 (sl) * | 2008-01-18 | 2015-11-30 | Eisai R&D Management Co., Ltd. | Kondenziran derivat aminodihidrotiazina |
| TWI593692B (zh) | 2013-03-12 | 2017-08-01 | 美國禮來大藥廠 | 四氫吡咯并噻嗪化合物 |
| TWI570127B (zh) * | 2014-09-15 | 2017-02-11 | 美國禮來大藥廠 | 結晶型N-[3-[(4aR,7aS)-2-胺基-6-(5-氟嘧啶-2-基)-4,4a,5,7-四氫吡咯并[3,4-d][1,3]噻嗪-7a-基]-4-氟-苯基]-5-甲氧基-吡嗪-2-甲醯胺、其用途及醫藥組合物 |
| AR103406A1 (es) * | 2015-01-30 | 2017-05-10 | Lilly Co Eli | Sal de tosilato |
-
2016
- 2016-01-13 AR ARP160100076A patent/AR103406A1/es unknown
- 2016-01-13 TW TW105100973A patent/TWI574969B/zh not_active IP Right Cessation
- 2016-01-22 ME MEP-2019-347A patent/ME03581B/me unknown
- 2016-01-22 CR CR20170287A patent/CR20170287A/es unknown
- 2016-01-22 SI SI201630517T patent/SI3250575T1/sl unknown
- 2016-01-22 EA EA201791229A patent/EA031330B1/ru not_active IP Right Cessation
- 2016-01-22 PE PE2017001211A patent/PE20171333A1/es unknown
- 2016-01-22 KR KR1020177020943A patent/KR101950129B1/ko not_active Expired - Fee Related
- 2016-01-22 HR HRP20192240TT patent/HRP20192240T1/hr unknown
- 2016-01-22 JP JP2017540253A patent/JP6723250B2/ja active Active
- 2016-01-22 DK DK16702654.1T patent/DK3250575T3/da active
- 2016-01-22 CN CN201680005234.2A patent/CN107108657B/zh active Active
- 2016-01-22 MD MDE20170309T patent/MD3250575T2/ro unknown
- 2016-01-22 SG SG11201706038PA patent/SG11201706038PA/en unknown
- 2016-01-22 PT PT167026541T patent/PT3250575T/pt unknown
- 2016-01-22 EP EP16702654.1A patent/EP3250575B1/en active Active
- 2016-01-22 MX MX2017009713A patent/MX2017009713A/es unknown
- 2016-01-22 LT LTEP16702654.1T patent/LT3250575T/lt unknown
- 2016-01-22 NZ NZ732381A patent/NZ732381A/en not_active IP Right Cessation
- 2016-01-22 PL PL16702654T patent/PL3250575T3/pl unknown
- 2016-01-22 MA MA41420A patent/MA41420B1/fr unknown
- 2016-01-22 TN TNP/2017/000332A patent/TN2017000332A1/en unknown
- 2016-01-22 CA CA2969475A patent/CA2969475C/en not_active Expired - Fee Related
- 2016-01-22 BR BR112017012149-2A patent/BR112017012149A2/pt not_active Application Discontinuation
- 2016-01-22 UA UAA201707108A patent/UA119581C2/uk unknown
- 2016-01-22 WO PCT/US2016/014423 patent/WO2016122968A1/en not_active Ceased
- 2016-01-22 RS RS20191663A patent/RS59730B1/sr unknown
- 2016-01-22 ES ES16702654T patent/ES2768782T3/es active Active
- 2016-01-22 AU AU2016211827A patent/AU2016211827B2/en not_active Ceased
- 2016-01-22 US US15/535,523 patent/US10080758B2/en active Active
- 2016-01-22 HU HUE16702654A patent/HUE048029T2/hu unknown
-
2017
- 2017-06-07 IL IL252754A patent/IL252754A0/en unknown
- 2017-06-08 ZA ZA2017/03937A patent/ZA201703937B/en unknown
- 2017-07-03 DO DO2017000159A patent/DOP2017000159A/es unknown
- 2017-07-06 SV SV2017005478A patent/SV2017005478A/es unknown
- 2017-07-25 CL CL2017001899A patent/CL2017001899A1/es unknown
- 2017-07-27 GT GT201700166A patent/GT201700166A/es unknown
- 2017-07-28 EC ECIEPI201748768A patent/ECSP17048768A/es unknown
- 2017-07-28 PH PH12017501356A patent/PH12017501356A1/en unknown
- 2017-08-01 CO CONC2017/0007810A patent/CO2017007810A2/es unknown
-
2019
- 2019-04-10 JP JP2019074951A patent/JP2019142902A/ja not_active Ceased
-
2020
- 2020-01-15 CY CY20201100033T patent/CY1122548T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201790407A1 (ru) | Зонды для визуализации белка хантингтина | |
| EP3414224A4 (en) | INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) | |
| MA42990A (fr) | Composés utiles en tant qu'immunomodulateurs | |
| AR101995A1 (es) | COMPUESTOS ANTAGONISTAS DE INTEGRINA avb6 | |
| MA40587A (fr) | Composés d'aminopyrimidinyle en tant qu'inhibiteurs de jak | |
| IL245314A0 (en) | Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor | |
| CR20150418A (es) | Compuestos de tetrahidropirrolotiazina | |
| BR112016026942A2 (pt) | geração de visualizações de direção curva por curva. | |
| LT3191461T (lt) | 6-karboksi-2-(3,5-dichlorfenil)-benzoksazolo kristalinės kietos formos | |
| MX2016011160A (es) | Tratamiento de afecciones asociadas con la hiperinsulinemia. | |
| EP3328379A4 (en) | BIS-HETEROARYL DERIVATIVES AS MODULATORS OF THE PROTEIN AGGREGATION | |
| EP3415146A4 (en) | INHIBITOR OF INFLAMMASOMAL ACTIVATION | |
| EP3504185A4 (en) | NEW SUBSTITUTED N'-HYDROXYCARBAMIMIDOYL-1,2,5-OXADIAZOLE COMPOUNDS AS INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) | |
| AR095097A1 (es) | Compuestos de fenoxietoxi | |
| EA201790400A1 (ru) | Зонды для визуализации белка хантингтина | |
| EP3384005A4 (en) | ARGININE SUPPLEMENT FOR IMPROVING EFFICIENCY IN GASFERMENTATION ACETOGENS | |
| EP3331843A4 (en) | CYCLOPROPANATION OF SUBSTITUTED ALKENES | |
| SV2017005478A (es) | Sal de tosilato n-[3-[(4ar,7as)-2-amino-6-(5-fluoropirimidina-2-il)-4,4a,5,7-tetrahidropirrolo[3,4-d][1,3]tiazina-7a-il]-4-fluoro-fenil]-5-metoxi-pirazina-2-carboxamida | |
| EP3171860C0 (en) | SOLID ORAL FORMULATION OF FENRETINIDE | |
| CL2017000645A1 (es) | Síntesis de ent-progesterona e intermediarios de la misma | |
| EP3472130A4 (en) | ALIPHATIC PROLINAMIDE DERIVATIVES | |
| CO2017001927A2 (es) | Formas cristalinas de n-[3-[(4ar,7as)-2-amino-6-(5- fluoropirimidin-2-il)-4,4a,5,7-tetrahidropirrolo[3,4-d][1,3]tiazin-7a-il]-4-fluoro-fenil]-5-metoxi-pirazin-2-carboxamida como inhibidores de bace | |
| DOP2017000016A (es) | Nueva sal de disoproxilo de tenofovir | |
| MA45787A (fr) | Composés de thiazolo-pyridine substitués en tant qu'inhibiteurs de malt1 |